PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that the following clinical and preclinical
abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as
well as for anti-PD-1 and anti-CD70 antibody candidates for cancer
treatment, are expected to be the subject of presentations at the Annual
Meeting of the American Society of Clinical Oncology, being held May
30-June 3, 2008 in Chicago:
Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma
-- "Antitumor response and new lesions in advanced melanoma patients on
ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:
Immunotherapy Session) -- Poster presentation and discussion from 2:00
p.m. to 6:00 p.m. local time on Friday, May 30, 2008.
-- "Long-term survival of patients with advanced melanoma who received
ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction
dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy
Session) - Poster presentation and discussion from 2:00 p.m. to 6:00
p.m. local time on Friday, May 30, 2008.
-- "Potential immune biomarkers of gastrointestinal toxicities and
efficacy in patients with advanced melanoma treated with ipilimumab
with or without prophylactic budesonide" (Abstract #3022, Developmental
Therapeutics: Immunotherapy Session) -- Poster presentation and
discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,
2008.
-- "Novel efficacy criteria for antitumor activity to immunotherapy using
the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"
(Abstract #3008, Developmental Therapeutics: Immunotherapy
Session) -- Oral presentation beginning at 4:30 p.m. local time one
Saturday, May 31, 2008.
-- "Effect of prior treatment status on the efficacy and safety of
ipilimumab monotherapy in treatment-naive and previously treated
patients with advanced melanoma" (Abstract #9055, Melanoma
Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time
on Saturday, May 31, 2008.
-- "An analysis of the effectiveness of specific guidelines for the
management of ipilimumab-mediated diarrhea/colitis: prevention of
gastrointestinal perforation and/or colectomy" (Abstract #9063,
Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.
local time on Saturday, May 31, 2008.
-- "Model-based evaluation of ipilimumab dosage regimen in patients with
advanced melanoma" (Abstract #9073, Melanoma Session) -- Poster
presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May
31, 2008.
-- "Safety and efficacy of ipilimumab with or without prophylactic
budesonide in treatment-naive and previously treated patients with
advanced melanoma" (Abstract #9010, Melanoma Session) -- Oral
presentation beginning at 10:15 a.m. local time on Sunday, June 1,
2008.
-- "Efficacy and safety of ipilimumab induction and maintenance dosing in
patients with advanced melanoma who progressed on one or more prior
therapies" (Abstract #9021, Melanoma Session) -- Poster presentation
and discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June
1, 2008.
-- "Disease control and long-term survival in chemotherapy-naive patients
with advanced melanoma treated with ipilimumab (MDX-010) with or
without dacarbazine" (Abstract #9022, Melanoma Session) -- Poster
presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on
Sunday, June 1, 2008.
-- "Dose effect of ipilimumab in patients with advanced melanoma: results
from a phase 2, randomized, dose-ranging study" (Abstract #9025,
Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.
to 6:00 p.m. local time on Sunday, June 1, 2008.
-- "Prolonged survival in objective responders to ipilimumab therapy"
(Abstract #20004) -- Publication only.
Response and Safety Data of Ipilimumab in Prostate
-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with
radiotherapy (XRT) in patients with metastatic castration resistant
prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for
Patients with Prostate Cancer Session) -- Oral presentation beginning
at 11:30 a.m. local time on Monday, June 2, 2008.
-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate
cancer and ipilimumab in patients with metastatic hormone-refractory
prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)
-- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on
Saturday, May 31, 2008.
Clinical and Preclinical Data of Additional Immunotherapy and
Antibody-Drug Conjugate Programs
-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal
antibody, in patients with selected refractory or relapse malignancies"
(Abstract #3006, Developmental Therapeutics: Immunotherapy
Session) -- Oral presentation beginning at 4:00 p.m. local time on
Saturday, May 31, 2008.
-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in
combination with ixabepilone in preclinical tumor models" (Abstract
#3048, Developmental Therapeutics: Immunotherapy Session) -- Poster
presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
2008.
-- "Effect of a fully human anti-CD70 antibody on apoptosis and
dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"
(Abstract #3073, Developmental Therapeutics: Immunotherapy
Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time
on Sunday, June 1, 2008.
More information about the ASCO Annual Meeting may be found at
http://www.asco.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.asco.org
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Nichol Harber, Corporate
Communications (media), +1-609-430-2880, x2214, both for Medarex,
Inc.
|
